Cerebrolysin vs Cortexin vs Semax: what the trials found

Reviewed 24 sourcesPublished by PepVault

Cerebrolysin, Cortexin and Semax side by side: a pig-brain mix, a cattle-brain extract and one lab-made peptide, where each is approved and what trials found.

Blonde-grey woman in a teal sweater plays an upright piano in a plant-filled room
Last reviewed
Sources
24
Questions
7
Compounds
2

The short answer

Cerebrolysin is a mixture of peptides from pig brain given by IV drip, Cortexin an extract of cow and pig brain cortex injected into muscle, and Semax one lab-made peptide used as nose drops. All three are used as medicines in Russia, and none is FDA approved. Cerebrolysin has the largest trials, and in the independent Cochrane review neither it nor Cortexin lowered deaths after a stroke.

Every number checked at its primary source · · 24 sources · How we research

Evidence: Mixed: large placebo-controlled trials for Cerebrolysin with no effect on stroke deaths in the independent review; Russian trials for Cortexin, mostly against usual care; small Russian studies for Semax; no trial of all three.

Blonde-grey woman in a teal sweater plays an upright piano in a plant-filled room

What is the difference between Cerebrolysin, Cortexin and Semax?

Two of them are broths of animal brain and one is a single molecule. Cerebrolysin is made by digesting pig brain proteins; when a Ghent University lab ran a sample through mass spectrometry, it counted 638 different peptides, mostly fragments of the brain's structural proteins, and no fragments of the known nerve growth factors1.

Cortexin is the Russian counterpart: its label lists polypeptides from the brain cortex of livestock, sold as a 10 mg powder vial with glycine added to keep it stable3. The Cochrane reviewers name the animals, cows and pigs, and note that its maker, Geropharm, positions it as a Cerebrolysin-like drug2. A review of its make-up lists neuropeptides, amino acids, vitamins and trace elements4.

Semax is different in kind: one synthetic chain of seven amino acids, which its Russian label calls an analogue of the ACTH 4-10 fragment, a piece of a pituitary hormone, with no hormonal action5. Every bottle of Semax holds the same molecule; no one has named a single active molecule in either brain extract14.

Side by sideCerebrolysinCortexinSemax
What it isHundreds of peptides from digested pig brain1Polypeptide extract of cow and pig brain cortex23One synthetic seven-amino-acid peptide5
Made byEVER Neuro Pharma, Austria9Geropharm, Russia3Peptogen, Russia; first registered by the Institute of Molecular Genetics56
How the trials gave itIV infusion, 30 mL a day for 10 to 21 days89Injection into muscle, 10 mg doses in 10-day courses1012Nose drops, 0.1% and 1%517
Largest placebo-controlled studyCASTA: 1,070 people after a stroke8272 people after a stroke10None in patients; single-dose brain-scan studies in 24 and 52 healthy volunteers1724
Independent reviewCochrane 2023: no fewer deaths after stroke2One trial, inside the same Cochrane review2None
A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault logs each dose by its route, nose drops or an injection, and reminds you at the time you set.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where is each one approved?

All three are used as medicines in Russia, Cortexin and Semax on prescription35. Semax 0.1% drops were first registered on December 20, 19946 and re-registered in March 20255; Cortexin's current registration dates from March 24, 20223. Cochrane describes Cerebrolysin as widely used for stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries2. Both brain extracts are on Russia's essential medicines list and in its national stroke guidelines, and Cerebrolysin is also on the essential lists of Slovakia, Romania, Vietnam, Uganda and Syria2; Semax is on the Russian list too5. Drugs@FDA lists no application for any of the three (searched November 2026)7.

That makes each one a prescription decision: whether to use any of them, and which, is a choice for a doctor who knows your history. For Semax's US compounding status, see our Semax and Selank guide.

What did the stroke trials find?

Stroke is the one condition all three were tested in, which makes it the fairest place to compare them. The designs differ more than the drugs: the Cerebrolysin trials and one Cortexin trial had a true placebo group, and no Semax stroke study did.

StudyDrugPeopleCompared withWhat it found
CASTA, 20128Cerebrolysin1,070Saline drip, 10 daysNo difference on the main measure at 90 days; in severe strokes, a post hoc look found 10.5% deaths against 20.2%
CARS, 20169Cerebrolysin208Saline, 21 daysBetter arm function on day 90; the authors call it exploratory and small
Aliferova, 201410Cortexin272PlaceboBest results with two 10-day courses; the abstract gives no figures
Belova, 201611Cortexin90Usual care, no placeboTwo courses gave fuller recovery than one course or none
Fedin, 202512Cortexin490IV form against muscle form, each with a dummy93.6% and 86.5% were largely independent at day 90; no untreated group
Gusev, 199715Semax30, plus 80 controlsUsual careSome speed-up in recovery, most in movement
Gusev, 201816Semax110Rehab without SemaxHigher BDNF, a nerve growth signal, in blood; faster daily-function recovery

The independent read is Cochrane's 2023 review, which pooled seven randomized trials of 1,773 people, six of Cerebrolysin and the 272-person Cortexin trial. Deaths showed little to no difference (risk ratio 0.96, moderate certainty), and no trial reported death or dependence at the end of follow-up2. In the Cortexin trial itself, 7 of 208 people on Cortexin died against none of 64 on placebo2. Across three Cerebrolysin trials, non-fatal serious adverse events were more common on the drug (risk ratio 2.39)2.

Which one is better?

No trial can say which works best, because none compared all three. On the evidence itself, Cerebrolysin leads: it is the only one with large placebo-controlled trials in international journals and an independent review of them. That record shows gains in rehab scores in the maker's funded trials9 and no change in deaths2. Cortexin comes second, with sizable Russian trials but mostly against usual care. Semax has the thinnest human record of the three. A stronger record is not a verdict for any one person: that call is the prescriber's.

The nearest thing to a head-to-head is a 2006 Russian stroke study that gave 45 patients Cortexin or Cerebrolysin: both helped about equally against no drug, and the authors favored Cortexin for fewer side effects and its price20. In a 40-person trial in early stroke recovery, Cortexin lost on two scores to another Russian peptide drug, Cellex14. In July 2026 Russia's pediatric neurologists placed Cortexin, Cerebrolysin and Semax together in their lower evidence group for ADHD21.

Head to head in rats, Cortexin and Cerebrolysin both improved recovery after a blocked brain artery, more than Actovegin; three authors worked for the Russian drug company Pharm-Holding18. In rat cells, Cerebrolysin kept nerve-like cells alive and Semax had no such effect22. Results in rats and cells often don't carry over to people.

Which one is used for what?

  • Cerebrolysin: stroke, brain injury and dementia. For vascular dementia, Cochrane found six trials of 597 people with better cognition, rated very low quality and possibly too small to matter19.
  • Cortexin: a wide Russian label, from poor blood flow to the brain and brain injury to epilepsy, fatigue states and developmental delay in children3. In 189 adults with chronic poor brain blood flow, 20 mg a day eased symptoms more than 10 mg, against no-drug controls13; a study of 635 children aged 3 to 7 had no control group23.
  • Semax: labelled in Russia for memory and thinking problems after vascular brain disease, stroke recovery and brain injury, and for attention problems from age 75.

What side effects were seen?

Semax's label lists one: mild irritation inside the nose with long use5. Cortexin's label lists very rare effects, including restlessness, poor sleep, a fast heartbeat and redness where it went in, and an allergic reaction3; in the 490-person trial, 60 people on the IV form and 41 on the muscle form had an adverse event, a difference the authors did not find significant12. Both Russian labels list pregnancy and breastfeeding as contraindications, and Semax's also rules it out with acute psychiatric states, anxiety disorders, a history of seizures and in children under 735. For Cerebrolysin, the signal worth knowing is Cochrane's higher rate of non-fatal serious events2.

When to get help Swelling of the face or throat, trouble breathing or a spreading rash after an injection is a reason to get emergency care.

What do people who use them report?

Commonly reported: clearer, quicker thinking is the effect people name most for Semax and for Cerebrolysin, with better mood next; with daily Semax, a few describe the effect fading. The few Cortexin reports describe a slower build over the first days of a 10-day course. Large injection volumes and headaches are the usual complaints with Cerebrolysin.

These are reports, not trial results: the trials measured recovery in people after a stroke or with dementia, never focus in healthy people. If your doctor starts a course, a short record makes the follow-up easier:

  • The product and maker as printed on the box, since the two brain extracts are not interchangeable.

PepVault logs each dose by its route, nose drops or an injection, and reminds you at the time you set. Set reminders in PepVault

Its side-effect log records a headache or a poor night against the product and the date, ready to show your doctor. Log it in PepVault

For Cerebrolysin's brain-injury and Alzheimer's trials in full, read our Cerebrolysin guide; for Semax beside its sister peptide, the Semax and Selank guide; and for the wider Russian peptide program, Khavinson bioregulators, explained.

Track it in the app

Sources

  1. Gevaert B, et al. Peptide profiling of Internet-obtained Cerebrolysin using HPLC-ESI ion trap and UHPLC-ion mobility-QTOF mass spectrometry. Drug Test Anal. 2015. PubMed 26017115
  2. Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023 (full text, included study Cortexin-Shamalov 2014). PubMed 37818733
  3. Vidal Russia. Cortexin 10 mg lyophilisate for intramuscular injection: registration ЛП-№(000636)-(РГ-RU) of March 24, 2022 (Geropharm), and the label. vidal.ru
  4. Gomazkov OA. Cortexin. Molecular mechanisms and targets of neuroprotective activity. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PubMed 26356623
  5. Vidal Russia. Semax 0.1% nasal drops: registration ЛП-№(009449)-(РГ-RU) of March 26, 2025 (Peptogen), and the label. vidal.ru
  6. RLS drug reference, registration record 94/294/10: Semax solution 0.1%, nasal drops, registered December 20, 1994 (holder: Institute of Molecular Genetics, Russian Academy of Sciences). rlsnet.ru
  7. U.S. Food and Drug Administration. Drugs@FDA (openFDA drugsfda endpoint), searches for cerebrolysin, cortexin and semax, November 2026: no matches. api.fda.gov
  8. Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA). Stroke. 2012. PubMed 22282884
  9. Muresanu DF, et al. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016. PubMed 26564102
  10. Aliferova VM, et al. Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PubMed 24874316
  11. Belova LA, et al. Efficacy of cortexin in acute and recovery periods of hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2016. PubMed 27845314
  12. Fedin AI, et al. Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes. Zh Nevrol Psikhiatr Im S S Korsakova. 2025. PubMed 41524350
  13. Fedin AI, et al. Dose-dependent effects of cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled study). Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PubMed 30335070
  14. Khabirov FA, et al. Comparison of the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2020. PubMed 33449527
  15. Gusev EI, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997. PubMed 11517472
  16. Gusev EI, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PubMed 29798983
  17. Lebedeva IS, et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med. 2018. PubMed 30225715
  18. Kurkin DV, et al. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One. 2021. PubMed 34260655
  19. Cui S, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019. PubMed 31710397
  20. Skorokhodov AP, et al. Comparative analysis of efficacy of certain neuroprotectors in ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2006. PubMed 18193579
  21. Lapochkin OL, et al. Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (ADHD) in children and adolescents. Zh Nevrol Psikhiatr Im S S Korsakova. 2026. PubMed 42910684
  22. Safarova ER, Shram SI, Grivennikov IA, Myasoedov NF. Trophic effects of nootropic peptide preparations cerebrolysin and semax on cultured rat pheochromocytoma. Bull Exp Biol Med. 2002. PubMed 12124658
  23. Zykov VP, et al. Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PubMed 29652302
  24. Panikratova YR, et al. Functional connectomic approach to studying Selank and Semax effects. Dokl Biol Sci. 2020. PubMed 32342318

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo